Serveur d'exploration Tocilizumab - Analysis (2020)

Index « AbsEn.i » - entrée « approved »
Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.
approvals < approved < approximately  Facettes :

List of bibliographic references

Number of relevant bibliographic references: 31.
[0-20] [0 - 20][0 - 31][20-30][20-40]
Ident.Authors (with country if any)Title
000007 (2020) Danièle Allali ; Marc Blondon ; Pascale Roux-Lombard ; David Spoerl[How to manage giant cell arteritis].
000010 (2020) Aline Pfefferle [Australie] ; Nicholas D. Huntington [Australie]You Have Got a Fast CAR: Chimeric Antigen Receptor NK Cells in Cancer Therapy
000034 (2020) Angelika Batta ; Bhupinder Singh Kalra ; Raj KhirasariaTrends in FDA drug approvals over last 2 decades: An observational study
000038 (2020) Maria C. Cid [Espagne] ; Roberto Ríos-Garcés [Espagne] ; Nekane Terrades-García [Espagne] ; Georgina Espígol-Frigolé [Espagne]Treatment of giant-cell arteritis: from broad spectrum immunosuppressive agents to targeted therapies.
000089 (2020) Jacob J. Adashek [États-Unis] ; Shumei Kato [États-Unis] ; Scott M. Lippman [États-Unis] ; Razelle Kurzrock [États-Unis]The paradox of cancer genes in non-malignant conditions: implications for precision medicine
000155 (2020) Meng Xu ; Congcong Liu ; Lishuang Guo ; Sirui YangSevere sepsis caused by serious gastrointestinal infection in sJIA patients treated with IL-6 receptor antagonist: a case report
000167 (2020) Peter A. Riedell ; Michael R. BishopSafety and efficacy of axicabtagene ciloleucel in refractory large B-cell lymphomas
000199 (2020) Tarek Mohamed Abd El-Aziz [États-Unis, Égypte] ; James D. Stockand [États-Unis]Recent progress and challenges in drug development against COVID-19 coronavirus (SARS-CoV-2) - an update on the status
000207 (2020) Shengyu Zhang ; Lei Li ; Aizong Shen ; Yongwu Chen ; Zhigang QiRational Use of Tocilizumab in the Treatment of Novel Coronavirus Pneumonia
000221 (2020) Yao-Chung Liu [Taïwan] ; Ting-An Lin [Taïwan] ; Hao-Yuan Wang [Taïwan] ; Po-Shen Ko [Taïwan] ; Chia-Jen Liu [Taïwan] ; Liang-Tsai Hsiao [Taïwan] ; Sheng-Hsuan Chien [Taïwan] ; Jyh-Pyng Gau [Taïwan]Pralatrexate as a bridge to allogeneic hematopoietic stem cell transplantation in a patient with advanced-stage extranodal nasal-type natural killer/T cell lymphoma refractory to first-line chemotherapy: a case report
000237 (2020) Zaid H. Temrikar [États-Unis] ; Satyendra Suryawanshi [États-Unis] ; Bernd Meibohm [États-Unis]Pharmacokinetics and Clinical Pharmacology of Monoclonal Antibodies in Pediatric Patients
000249 (2020) Mark P. Lythgoe [Royaume-Uni] ; Paul Middleton [Royaume-Uni]Ongoing Clinical Trials for the Management of the COVID-19 Pandemic
000251 (2020) Simona Di Giambenedetto ; Arturo Ciccullo ; Alberto Borghetti ; Giovanni Gambassi [Italie] ; Francesco Landi [Italie] ; Elena Visconti ; Lorenzo Zileri Dal Verme ; Roberto Bernabei [Italie] ; Enrica Tamburrini ; Roberto Cauda ; Antonio Gasbarrini [Italie]Off-label Use of Tocilizumab in Patients with SARS-CoV-2 Infection.
000260 (2020) Ruksana HudaNew Approaches to Targeting B Cells for Myasthenia Gravis Therapy
000289 (2020) Ibrahim Yakoub-Agha [France] ; Christian Chabannon [France] ; Peter Bader [Allemagne] ; Grzegorz W. Basak [Pologne] ; Halvard Bonig [Allemagne] ; Fabio Ciceri [Italie] ; Selim Corbacioglu [Allemagne] ; Rafael F. Duarte [Espagne] ; Hermann Einsele [Allemagne] ; Michael Hudecek [Allemagne] ; Marie José Kersten [Pays-Bas] ; Ulrike Köhl [Allemagne] ; Jürgen Kuball [Pays-Bas] ; Stephan Mielke [Suède] ; Mohamad Mohty [France] ; John Murray [Royaume-Uni] ; Arnon Nagler [Israël] ; Stephen Robinson [Royaume-Uni] ; Riccardo Saccardi [Italie] ; Fermin Sanchez-Guijo [Espagne] ; John A. Snowden [Royaume-Uni] ; Micha Srour [France] ; Jan Styczynski [Pologne] ; Alvaro Urbano-Ispizua [Espagne] ; Patrick J. Hayden [Irlande (pays)] ; Nicolaus Kröger [Allemagne]Management of adults and children undergoing chimeric antigen receptor T-cell therapy: best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE)
000318 (2020) Peter Uciechowski [Allemagne] ; Wolfram C M. Dempke [Allemagne]Interleukin-6: A Masterplayer in the Cytokine Network.
000320 (2020) Rachel A. O Eefe ; Neil E. Bhola ; David S. Lee ; Daniel E. Johnson ; Jennifer R. GrandisInterleukin 6 is increased in preclinical HNSCC models of acquired cetuximab resistance, but is not required for maintenance of resistance
000340 (2020) Bong-Ha Shin [États-Unis] ; Matthew J. Everly [États-Unis] ; Hao Zhang [États-Unis] ; J. Choi [États-Unis] ; Ashley Vo [États-Unis] ; Xiaohai Zhang [États-Unis] ; Edmund Huang [États-Unis] ; Stanley C. Jordan [États-Unis] ; Mieko Toyoda [États-Unis]Impact of Tocilizumab (Anti-IL-6R) Treatment on Immunoglobulins and Anti-HLA Antibodies in Kidney Transplant Patients With Chronic Antibody-mediated Rejection.
000348 (2020) Sisi Xie ; Shu Li ; Jing Tian ; Fen LiIguratimod as a New Drug for Rheumatoid Arthritis: Current Landscape
000411 (2020) Lutz Wollin [Allemagne] ; Dieudonnée Togbe [France] ; Bernhard Ryffel [France]Effects of Nintedanib in an Animal Model of Liver Fibrosis
000438 (2020) Boris Fehse [Allemagne] ; Anita Badbaran [Allemagne] ; Carolina Berger [Allemagne] ; Tanja Sonntag [Allemagne] ; Kristoffer Riecken [Allemagne] ; Maria Geffken [Allemagne] ; Nicolaus Kröger [Allemagne] ; Francis A. Ayuk [Allemagne]Digital PCR Assays for Precise Quantification of CD19-CAR-T Cells after Treatment with Axicabtagene Ciloleucel

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/TocilizumabV1/Data/2020/Analysis
HfdIndexSelect -h $EXPLOR_AREA/Data/2020/Analysis/AbsEn.i -k "approved" 
HfdIndexSelect -h $EXPLOR_AREA/Data/2020/Analysis/AbsEn.i  \
                -Sk "approved" \
         | HfdSelect -Kh $EXPLOR_AREA/Data/2020/Analysis/biblio.hfd 

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    TocilizumabV1
   |flux=    2020
   |étape=   Analysis
   |type=    indexItem
   |index=    AbsEn.i
   |clé=    approved
}}

Wicri

This area was generated with Dilib version V0.6.34.
Data generation: Fri May 22 09:34:00 2020. Site generation: Sun Mar 28 09:01:19 2021